Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study
Recommended Citation
Mehta V, Stein-Gold L, Golant A, Lio P, Chovatiya R, Dawson Z, Pierce E, DeLuca-Carter LA, Haughton J, Piercy J, Anderson P, Geng B. Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study. J Allergy Clin Immunol 2025; 155(2):1.
Document Type
Conference Proceeding
Publication Date
2-1-2025
Publication Title
J Allergy Clin Immunol
Abstract
Rationale: Despite the availability of multiple novel targeted therapies for atopic dermatitis (AD), key treatment attributes influencing physician preferences are not well understood. We explored treatment attribute preferences and strategies for moderate-to-severe AD among allergists and dermatologists. Methods: Data were drawn from Adelphi AD Disease Specific Programme™, cross-sectional survey of US-based physicians (Oct’22–Mar’23). Physicians rated importance of treatment attributes in managing moderate-to-severe AD (scale 1–5: 1=‘not important’; 5=‘extremely important’), stated which treatments they typically used at first/second/third-line, and how they perceived oral JAK inhibitors (JAKi) versus biologics. Data are summarized descriptively. Results: Allergists (n=19) and dermatologists (n=70) similarly rated several treatment attributes as extremely important: relief from pruritus (79%;70%); improvement of skin lesions (68%;63%), pain/soreness/discomfort (68%;60%) and achieving clear skin (47%;46%). Numerically, more allergists (versus dermatologists) rated reducing sleep disruption (89%;57%) and flares (84%;59%); long-term control (84%;64%) and safety (84%;61%); controlling skin infection (74%;49%); affordability (68%;46%); and sustained efficacy (63%;47%) as extremely important. Preferred treatment placement for severe AD varied between allergists and dermatologists (first-line: emollients [79%;50%], antihistamines [58%;36%], topical corticosteroids (TCS) [moderate-potency:58%;44%; high-potency:47%;67%]; second-line: high-potency TCS [32%;29%], biologics [32%;49%], topical JAKi [16%;40%]; third-line: biologics [63%;53%], Oral JAKi [58%;63%], systemic immunosuppressants [42%;27%]). Overall treatment perception of oral JAKi versus biologics varied amongst allergists and dermatologists (much/somewhat worse [47%;29%], equivalent [37%;39%], somewhat/much better [16%;33%]). Conclusions: Specialists’ preferences for treatment attributes and strategies, and perceptions of different advanced systemic therapies for moderate-to-severe AD, varied. Further data are needed to assess whether preferences/perceptions of advanced systemics change, and influence prescribing decisions as new treatments become available.
Volume
155
Issue
2
First Page
1
